iVeena Announces Successful Completion of Pre-IND Meeting with FDA
SALT LAKE CITY--(BUSINESS WIRE)--iVeena Delivery Systems (iVeena), a clinical stage biopharmaceutical company with developmental products in keratoconus and pediatric myopia, announces successful completion of a pre-IND (Investigational New Drug) meeting with the U.S. Food and Drug Administration (FDA) regarding the development plan for a novel pharmacologic treatment of pediatric myopia. IVMED-85 enables physiologic crosslinking in the sclera and cornea to arrest progression of myopia. The inv